6 active not recruiting. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Active not recruiting 6 |
Follow Thrombocytosis: new trials by email Literature Review of Thrombocytosis trials Research Report on Thrombocytosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) Bomedemstat, Hydroxyurea, Bomedemstat placebo - Essential Thrombocythemia | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 300 | 2024-07-16 | 2026-08-27 |
| A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) Bomedemstat, Anagrelide, Busulfan - Essential Thrombocythemia | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 340 | 2023-12-31 | 2026-10-02 |
| A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients Ropeginterferon alfa-2b (BESREMi®) - Essential Thrombocythaemia | Phase 3 | Active not recruiting | AOP Orphan Pharmaceuticals AG | 117 | 2023-12-04 | 2024-12-19 |
| A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV P1101 (Ropeginterferon alfa-2b-njft), Ropeginterferon alfa-2b-njft (P1101) - Polycythemia Vera | Phase 3 | Active not recruiting | PharmaEssentia | 111 | 2022-10-26 | 2025-08-13 |
| A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment Imetelstat, Best Available Therapy (BAT) - Myelofibrosis | Phase 3 | Active not recruiting | Geron Corporation | 327 | 2021-04-12 | 2026-07-08 |
| Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance Ropeginterferon alfa-2b, Anagrelide - Essential Thrombocythemia | Phase 3 | Active not recruiting | PharmaEssentia | 174 | 2020-08-25 | 2026-07-22 |
Thrombocythemia, Essential (5) · Myeloproliferative Disorders (2) · Polycythemia (2) · Polycythemia Vera (1) · Primary Myelofibrosis (1)
Blood Platelet Disorders (6) · Bone Marrow Diseases (6) · Hematologic Diseases (6) · Hemic and Lymphatic Diseases (6) · Blood Coagulation Disorders (5) · Hemorrhagic Disorders (5) · Myeloproliferative Disorders (4) · Bone Marrow Neoplasms (1) · Hematologic Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1)
anagrelide (2) · bomedemstat (2) · Busulfan (1) · GRN163L peptide (1) · Hydroxyurea (1) · imetelstat (1) · ruxolitinib (1)
Merck Sharp & Dohme LLC (2) · PharmaEssentia (2) · AOP Orphan Pharmaceuticals AG (1) · Geron Corporation (1)
United States (5) · Canada (4) · France (4) · Germany (4) · Hungary (4) · Italy (4) · Poland (4) · Spain (4) · Taiwan (4) · Argentina (3) · Australia (3) · Austria (3) · China (3) · Colombia (3) · Hong Kong (3)
Craig Zimmerman, PhD (1) · Joe Eid (1) · Ole Zagrijtschuk, MD, PhD (1) · Toshiaki Sato, MD/PhD (1)
PMID 35510486, PMID 35924546, PMID 41193116
2023 (3)